Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We report findings from a phase 1/1b study in East Asian patients with AML or MDS, conducted to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Handa, Hiroshi, Cheong, June-Won, Onishi, Yasushi, Iida, Hiroatsu, Kobayashi, Yukio, Kim, Hyeoung-Joon, Chiou, Tzeon-Jye, Izutsu, Koji, Tsukurov, Olga, Zhou, Xiaofei, Faessel, Helene, Yuan, Ying, Sedarati, Farhad, Faller, Douglas V., Kimura, Akiko, Wu, Shang-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097234/
https://www.ncbi.nlm.nih.gov/pubmed/35545778
http://dx.doi.org/10.1186/s13045-022-01264-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097234/
https://www.ncbi.nlm.nih.gov/pubmed/35545778
http://dx.doi.org/10.1186/s13045-022-01264-w

Ejemplares similares